Stewart-Treves Syndrome
No Results
No Results
processing….
Stewart-Treves syndrome is a rare, deadly cutaneous angiosarcoma that develops in long-standing chronic lymphedema. [1, 2, 3, 4] See the image below.
Most commonly, this tumor is a result of lymphedema induced by radical mastectomy to treat breast cancer. Unfortunately, although the breast cancer may be cured with such radical surgery, this second primary cancer may be responsible for the patient’s worsening course. The term Stewart-Treves syndrome is broadly applied to an angiosarcoma that arises in a chronically lymphedematous region due to any cause, including congenital lymphedema and other causes of secondary lymphedema unassociated with mastectomy. As reported by Durr et al in 2004, this lymphangiosarcoma occurs as a rare complication. [5] Lymphangiosarcoma is a misnomer because this malignancy seems to arise from blood vessels instead of lymphatic vessels. A more appropriate name is hemangiosarcoma.
In 1906, Lowenstein first described angiosarcoma in a patient’s arm that had been affected by severe posttraumatic lymphedema for 5 years. [6] In 1948, Stewart and Treves reported this rare secondary malignancy in 6 cases of angiosarcoma in postmastectomy lymphedema. [7] They recognized that an edematous arm after radical mastectomy for breast cancer may suggest recurrent breast cancer, but that long-standing chronic edema without recurrent cancer may occasionally produce “a heretofore unrecognized and unreported sequel … long after the malignant breast neoplasm has apparently been arrested … a new specific tumor.” Stewart and Treves suggested that these angiosarcomas were probably not observed previously because they were mistaken for recurrent, inoperable, cutaneous manifestations of breast cancer.
Lymphangiosarcoma has been described in Milroy disease and in idiopathic, congenital, traumatic, or filarial lymphedema. [8, 9, 10]
The pathogenic mechanism by which lymphedema may induce angiosarcoma has been the subject of controversy. Stewart and Treves found a high incidence of third malignancies in patients with postmastectomy angiosarcoma. Thus, they speculated that a systemic carcinogenic factor was the main causative factor in the pathogenesis of lymphangiosarcomas.
In 1979, Schreiber and others postulated the concept of local immunodeficiency in the presence of lymphedema. [11] This theory is supported by experimental evidence. In 1960, Stark and associates demonstrated that homograft skin transplanted to lymphedematous arms survive much longer than those transplanted to healthy arms. [12] Therefore, lymphedema may cause some degree of local immunodeficiency and lead to oncogenesis.
The possibility that radiation therapy has an important role in the induction of lymphangiosarcoma is also postulated. [13] Sternby et al reported that in their study, the patient with the shortest interval between radical mastectomy and the onset of the tumor (8 mo) received both preoperative radiation therapy of the breast and involved axillary lymph nodes followed by fractionated radiation. [14] Others suggest that irradiation is not an essential factor in the pathogenesis of this tumor. Finally, irradiation may be an indirect cause of lymphangiosarcomas because it may cause axillary node sclerosis and thereby accelerate and aggravate the edema.
Clinical data from Swedish women with previous breast cancer who developed angiosarcomas/lymphangiosarcomas on the thoracic wall/upper extremity between 1958 and 2008 showed 31 angiosarcomas developed at a median age of 71 years. [15] The 14 women treated for breast cancer with radical mastectomy and radiotherapy from 1949-1988 developed angiosarcomas in edematous arms after a median 11 years, whereas 17 females treated by segmental resection, antihormonal treatment, and radiotherapy from 1980-2005 developed angiosarcomas in the irradiated field on the thoracic wall after a median 7.3 years.
A hemangiogenic and lymphangiogenic origin of this angiosarcoma has been documented. [16]
The most important single causative agent in Stewart-Treves syndrome is prolonged chronic lymphedema. Although Stewart-Treves syndrome develops after radical mastectomy in most patients, lymphangiosarcoma also develops in other forms of acquired lymphedema and in congenital lymphedema. Causes for such secondary lymphedema may include trauma, surgical invasion of the groin for the treatment of penile or cervical cancer, filariasis, idiopathic acquired lymphedema, vascular stasis, and morbid obesity.
Edema secondary to cardiac or renal disease is not associated with this malignancy. Thus, edema alone is not sufficient to cause lymphangiosarcoma. Perhaps additional factors such as a genetic predisposition are required.
Currently, approximately 400 cases of Stewart-Treves syndrome are reported in the world literature. In 1962, Schirger calculated that the incidence of this disease is 0.45% in patients who survive at least 5 years after radical mastectomy. [17] Another analysis calculated it as occurring in 0.03% of patients surviving 10 or more years after radical mastectomy. [18]
As a result of the increase in conservative treatment for breast carcinoma and improvement of operative and radiation therapy techniques, the prevalence of Stewart-Treves syndrome has decreased. [3]
No racial predominance exists for Stewart-Treves syndrome.
Most patients with Stewart-Treves syndrome are women with a history of breast cancer that has been treated with radical mastectomy, which causes chronic lymphedema.
Stewart-Treves syndrome usually occurs in middle-aged or elderly women, a few years or many years after mastectomy.
In 1981, Sordillo and associates reported a peak incidence in persons aged 65-70 years. [19] In 1972, Woodward et al described a series of 23 patients in a review of 163 cases of Stewart-Treves syndrome from the literature. [20] They recorded an average patient age of 68.8 years at the onset of lymphangiosarcoma; the youngest patient was aged 44 years and the oldest, 84 years.
The prognosis is dismal. Lymphangiosarcomas are extremely aggressive tumors with a high local recurrence rate and a tendency to metastasize early to many areas.
Long-term survivors are the exceptions. The 5-year survival rate reported by Sordillo et al in 1981 was 13.6%, [19] In 1987, Hultberg found that patients with Stewart-Treves syndrome had a mean survival of 20 months after tumor onset. [21] Untreated patients have an average survival of 5-8 months. A more recent analysis showed the overall 5-year survival was 16%. [22]
Metastatic angiosarcoma to the lungs and chest wall are the most common cause of death in patients with Stewart-Treves syndrome. Metastases to the liver and bones can also occur. Lymphangiomas are associated with a high rate of local recurrence and metastasis, even after aggressive surgical treatment.
Early diagnosis and treatment by radical ablative surgery or possibly other approaches may afford an improved prognosis; patients at risk should be carefully monitored. [23, 24]
Patients should be informed about the significance of prolonged chronic lymphedema and about how to reduce and control it. Patients should be encouraged to seek early medical attention if they notice unexplained skin changes or unresolved lymphedema. Patients should be educated about complications, such as recurrent infections, deep venous thrombosis, and malignancies, that can occur with lymphedema.
For patient education resources, visit the Women’s Health Center and Cancer Center. Also, see the patient education articles Mastectomy and Breast Cancer.
Gonne E, Collignon J, Kurth W, et al. [Angiosarcoma consecutive to chronic lymphoedema: a Stewart-Treves syndrome]. Rev Med Liege. 2009 Jul-Aug. 64(7-8):409-13. [Medline].
Schwartz RA. Kaposi’s sarcoma. Schwartz RA, ed. Skin Cancer: Recognition and Management. 1988. 80-8.
Sharma A, Schwartz RA. Stewart-Treves syndrome: pathogenesis and management. J Am Acad Dermatol. 2012 Dec. 67(6):1342-8. [Medline].
Lee R, Saardi KM, Schwartz RA. Lymphedema-related angiogenic tumors and other malignancies. Clin Dermatol. 2014 Sep-Oct. 32 (5):616-20. [Medline].
Dürr HR, Pellengahr C, Nerlich A, Baur A, Maier M, Jansson V. Stewart-Treves syndrome as a rare complication of a hereditary lymphedema. Vasa. 2004 Feb. 33(1):42-5. [Medline].
Lowenstein S. Der atiologische zusammenhang zwischen akutem ein-maligem trauma und sarkon. Beitr Z klin Clir. 1906. 48:780.
Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema: A report of six cases in elephantiasis chirurgica. Cancer. 1948. 1:64-81.
Hallel-Halevy D, Yerushalmi J, Grunwald MH, Avinoach I, Halevy S. Stewart-Treves syndrome in a patient with elephantiasis. J Am Acad Dermatol. 1999 Aug. 41(2 Pt 2):349-50. [Medline].
Offori TW, Platt CC, Stephens M, Hopkinson GB. Angiosarcoma in congenital hereditary lymphoedema (Milroy’s disease)–diagnostic beacons and a review of the literature. Clin Exp Dermatol. 1993 Mar. 18(2):174-7. [Medline].
Farhat MM, Le Guern A, Peugniez C, Dabouz F, Quinchon JF, Modiano P. [Angiosarcoma in primary lymphoedema: A rare complication]. Ann Dermatol Venereol. 2018 Apr. 145 (4):266-269. [Medline].
Schreiber H, Barry FM, Russell WC, Macon WL 4th, Ponsky JL, Pories WJ. Stewart-Treves syndrome. A lethal complication of postmastectomy lymphedema and regional immune deficiency. Arch Surg. 1979 Jan. 114(1):82-5. [Medline].
Stark RB, Dwyer EM, De Forest M. Effect of surgical ablation of regional lymph nodes on survival of homografts. Ann NY Acad Sci. 1960. 87:140-148.
Cabral ANF, Rocha RH, Amaral ACVD, Medeiros KB, Nogueira PSE, Diniz LM. Cutaneous angiosarcoma: report of three different and typical cases admitted in a unique dermatology clinic. An Bras Dermatol. 2017 Mar-Apr. 92 (2):235-238. [Medline].
Sternby NH, Gynning I, Hogeman KE. Postmastectomy angiosarcoma. Acta Chir Scand. 1961. 121:420-432.
Styring E, Fernebro J, Jonsson PE, et al. Changing clinical presentation of angiosarcomas after breast cancer: from late tumors in edematous arms to earlier tumors on the thoracic wall. Breast Cancer Res Treat. 2010 Jan 20. [Medline].
Stanczyk M, Gewartowska M, Swierkowski M, Grala B, Maruszynski M. Stewart-Treves syndrome angiosarcoma expresses phenotypes of both blood and lymphatic capillaries. Chin Med J (Engl). 2013 Jan. 126(2):231-7. [Medline].
Schirger A. Postoperative lymphedema: etiologic and diagnostic factors. Med Clin North Am. 1962 Jul. 46:1045-50. [Medline].
Wierzbicka-Hainaut E, Guillet G. [Stewart-Treves syndrome (angiosarcoma on lyphoedema): A rare complication of lymphoedema]. Presse Med. 2010 Dec. 39(12):1305-8. [Medline].
Sordillo PP, Chapman R, Hajdu SI, Magill GB, Golbey RB. Lymphangiosarcoma. Cancer. 1981 Oct 1. 48(7):1674-9. [Medline].
Woodward AH, Ivins JC, Soule EH. Lymphangiosarcoma arising in chronic lymphedematous extremities. Cancer. 1972 Aug. 30(2):562-72. [Medline].
Hultberg BM. Angiosarcomas in chronically lymphedematous extremities. Two cases of Stewart-Treves syndrome. Am J Dermatopathol. 1987 Oct. 9(5):406-12. [Medline].
Styring E, Fernebro J, Jönsson PE, Ehinger A, Engellau J, Rissler P, et al. Changing clinical presentation of angiosarcomas after breast cancer: from late tumors in edematous arms to earlier tumors on the thoracic wall. Breast Cancer Res Treat. 2010 Aug. 122(3):883-7. [Medline].
Felmerer G, Dowlatshahi AS, Stark GB, Földi E, Földi M, Ahls MG, et al. Lymphangiosarcoma: Is Stewart-Treves Syndrome a Preventable Condition?. Lymphat Res Biol. 2016 Mar. 14 (1):35-9. [Medline].
Campana LG, Valpione S, Tosi A, Rastrelli M, Rossi CR, Aliberti C. Angiosarcoma on Lymphedema (Stewart-Treves Syndrome): A 12-Year Follow-up after Isolated Limb Perfusion, Limb Infusion, and Electrochemotherapy. J Vasc Interv Radiol. 2016 Mar. 27 (3):444-6. [Medline].
Tomita K, Yokogawa A, Oda Y, Terahata S. Lymphangiosarcoma in postmastectomy lymphedema (Stewart-Treves syndrome): ultrastructural and immunohistologic characteristics. J Surg Oncol. 1988 Aug. 38(4):275-82. [Medline].
Yap BS, Yap HY, McBride CM, Bodey GP. Chemotherapy for postmastectomy lymphangiosarcoma. Cancer. 1981 Mar 1. 47(5):853-6. [Medline].
Yamane H, Ochi N, Tabayashi T, Takigawa N. Stewart-treves syndrome after cervical cancer. Intern Med. 2012. 51(5):513. [Medline].
Sánchez-Medina MT, Acosta A, Vilar J, Fernández-Palacios J. Angiosarcoma in Chronic Lymphedema (Stewart-Treves Syndrome). Actas Dermosifiliogr. 2012 Feb 23. [Medline].
Ise M, Funakoshi T, Furuichi Y, Honda H, Fujio Y, Amagai M, et al. Case of angiosarcoma on the abdominal wall, an extremely rare variant, putatively shared the pathogenesis with Stewart-Treves syndrome. J Dermatol. 2015 Apr. 42 (4):426-7. [Medline].
Bassotti A, Driban N, Huczak L, Zaccarria S. Angiosarcoma en linfedema cronico posmastectomia (Sindrome de Stewart-Treves). Med Rev. 2008. 4:1-20.
Stanczyk M, Gewartowska M. Stewart-Treves syndrome. Indian J Med Res. 2014 Jan. 139(1):179. [Medline].
Schwartz RA, Kardashian JF, McNutt NS, Crain WR, Welch KL, Choy SH. Cutaneous angiosarcoma resembling anaplastic Kaposi’s sarcoma in a homosexual man. Cancer. 1983 Feb 15. 51(4):721-6. [Medline].
Salameire D, Templier I, Charles J, et al. An “anaplastic” Kaposi’s sarcoma mimicking a Stewart-Treves syndrome. A case report and a review of literature. Am J Dermatopathol. 2008 Jun. 30(3):265-8. [Medline].
Kunkel T, Mylonas I, Mayr D, Friese K, Sommer HL. Recurrence of secondary angiosarcoma in a patient with post-radiated breast for breast cancer. Arch Gynecol Obstet. 2008 Nov. 278(5):497-501. [Medline].
Nakazono T, Kudo S, Matsuo Y, et al. Angiosarcoma associated with chronic lymphedema (Stewart-Treves syndrome) of the leg: MR imaging. Skeletal Radiol. 2000 Jul. 29(7):413-6. [Medline].
Schindera ST, Streit M, Kaelin U, Stauffer E, Steinbach L, Anderson SE. Stewart-Treves syndrome: MR imaging of a postmastectomy upper-limb chronic lymphedema with angiosarcoma. Skeletal Radiol. 2005 Mar. 34(3):156-60. [Medline].
Li B, Wang Z. Stewart-Treves syndrome: Magnetic resonance imaging data compared with pathological results from a single center. Oncol Lett. 2018 Jan. 15 (1):1113-1118. [Medline].
Dawlatly SL, Dramis A, Sumathi VP, Grimer RJ. Stewart-Treves syndrome and the use of positron emission tomographic scanning. Ann Vasc Surg. 2011 Jul. 25(5):699.e1-3. [Medline].
Chen YR, Hsieh TC, Yen KY, Kao CH. Distant Metastases in a Young Female With Stewart-Treves Syndrome Demonstrated by an FDG-PET/CT Scan. Clin Nucl Med. 2014 Feb 20. [Medline].
McConnell AH, Haslam P. Angiosarcoma in post-mastectomy lymphedema: report of five cases and review of the literature. Br J Surg. 1959. 46:322-32.
Grobmyer SR, Daly JM, Glotzbach RE, Grobmyer AJ 3rd. Role of surgery in the management of postmastectomy extremity angiosarcoma (Stewart-Treves syndrome). J Surg Oncol. 2000 Mar. 73(3):182-8. [Medline].
Breidenbach M, Rein D, Schmidt T, et al. Intra-arterial mitoxantrone and paclitaxel in a patient with Stewart-Treves syndrome: selection of chemotherapy by an ex vivo ATP-based chemosensitivity assay. Anticancer Drugs. 2000 Apr. 11(4):269-73. [Medline].
Goetze S, Schmook T, Audring H, Ziegenbein C, Worm M, Schulze P. [Successful treatment of Stewart-Treves syndrome with liposomal doxorubicin]. J Dtsch Dermatol Ges. 2004 Jan. 2(1):49-52. [Medline].
Paydas S, Yapar Z, Gonlusen G. Stewart-Treves syndrome: questionable response to weekly paclitaxel. Chemotherapy. 2010. 56(1):66-8. [Medline].
Fujisawa Y, Ito M, Mori K, Okada S, Nakamura Y, Kawachi Y, et al. Intra-arterial mitoxantrone/paclitaxel in angiosarcoma of the lower limb associated with chronic lymphedema (Stewart-Treves syndrome) in a patient with cervical cancer. Eur J Dermatol. 2011 Jan 14. [Medline].
Furue M, Yamada N, Takahashi T, et al. Immunotherapy for Stewart-Treves syndrome. Usefulness of intrapleural administration of tumor-infiltrating lymphocytes against massive pleural effusion caused by metastatic angiosarcoma. J Am Acad Dermatol. 1994 May. 30(5 Pt 2):899-903. [Medline].
Roy P, Clark MA, Thomas JM. Stewart-Treves syndrome–treatment and outcome in six patients from a single centre. Eur J Surg Oncol. 2004 Nov. 30(9):982-6. [Medline].
Robert A Schwartz, MD, MPH Professor and Head of Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, Rutgers New Jersey Medical School; Visiting Professor, Rutgers University School of Public Affairs and Administration
Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, New York Academy of Medicine, American Academy of Dermatology, American College of Physicians, Sigma Xi
Disclosure: Nothing to disclose.
Geover Fernandez, MD, FAAD Staff Physician, Department of Dermatology, Rutgers New Jersey Medical School
Geover Fernandez, MD, FAAD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Society for MOHS Surgery
Disclosure: Nothing to disclose.
Michael J Wells, MD, FAAD Dermatologic/Mohs Surgeon, The Surgery Center at Plano Dermatology
Michael J Wells, MD, FAAD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Texas Medical Association
Disclosure: Nothing to disclose.
Christen M Mowad, MD Professor, Department of Dermatology, Geisinger Medical Center
Christen M Mowad, MD is a member of the following medical societies: Alpha Omega Alpha, Noah Worcester Dermatological Society, Pennsylvania Academy of Dermatology, American Academy of Dermatology, Phi Beta Kappa
Disclosure: Nothing to disclose.
William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine
William D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology
Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier; WebMD.
Abby S Van Voorhees, MD Assistant Professor, Director of Psoriasis Services and Phototherapy Units, Department of Dermatology, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania
Abby S Van Voorhees, MD is a member of the following medical societies: American Academy of Dermatology, Women’s Dermatologic Society, National Psoriasis Foundation, American Medical Association, Phi Beta Kappa, Sigma Xi
Disclosure: Received honoraria from Amgen for consulting; Received honoraria from Abbott for consulting; Partner received salary from Merck for management position; Received honoraria from Abbott for speaking and teaching; Received honoraria from Amgen for review panel membership; Received honoraria from Centocor for consulting; Received honoraria from Leo for consulting; Received none from Merck for other.
Stewart-Treves Syndrome
Research & References of Stewart-Treves Syndrome|A&C Accounting And Tax Services
Source
0 Comments